



International Conference on Drug Prevention, Treatment and Care – Inspiration and Direction This project is funded by ISSPUP, Vienna, I-3 July 2019

COPOLAD contribution to promote evidence-based policy and programmes in the field of drug demand reduction in in Latin American and the Caribbean countries

Teresa Salvador-I livina Director

Austria Belgium Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Greece Hungary Ireland Slovak Republic Slovenia Latvia Lithuania Luxembourg Malta Netherlands Poland Portugal Sweden United Kingdom

EUROPEAN UNION

LATIN AMERICA & THE CARIBBEAN

Antiqua and Barbuda Argentina Bahamas Barbados Belize Bolivia Brazil Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Nicaragua Panama Paraguay Peru St. Kitts and Nevis St. Lucia St. Vincent and the Grenadines Suriname Trinidad and Tobago Uruguay Venezuela

COPOLAD CONSORTIUM

- SEDRONAR (Argentina)
 SENAD (Brazil)
 SENDA (Chile)
 MINJUSTICIA (Colombia)
- ICD (Costa Rica)
 CND (Cuba)
 VLADA (Czech Republic)
 CND (Dominican Republic)
- MREMH (Ecuador)
 CNA (El Salvador)
 GIZ (Germany)
 DNII (Honduras)
- CONADIC (Mexico)
 CONAPRED (Panama)
 DEVIDA (Peru)
 NBDP (Poland) SICAD (Portugal) • NAA (Romania) • DGPNSD (Spain) • NDC (Trinidad and Tobago) • IND (Uruguay) • ONA (Venezuela) •
- EMCDDA
- CICAD /OAS PAHO / WHO •
- AIAMPIDPCRIOD









Unusual "cooperation" programme

Partners:

 National Agencies and other institutions responsible for drugs policy

Collaborating institutions:

- European Agency EMCDDA
- Key multilateral Agencies CICAD and PAHO
- Bi-regional networks: IDPC & RIOD







4 Decades of DDR Developments





Magical Thinking

- Response to social alarm
- Ideological bias
- Voluntary interventions (goodwill)
- Weak theoretical bases
- Intention to "save the world" with no resources
- Isolated actions
- NO or Poor planning
- Lack of evaluation
- Anything goes, as long as "something" is done...

- 1) Increasing institutional experience
- 2) Increasing research findings
- 3) UNGASS 2016
- 4) S Development objectives 2030

Progress towards:

- Needs assessment
- Attention to evidence
- Public policy
- Evidence-based intervention models
- Considering cost-effectiveness (priorities)
- Strategies & Plans
- Planning
- Evaluation
- Good intentions might do more harm than good



COPOLAD II: AIM



Support the enhancement of public policy on drugs, committed to **some basic principles**, ...

... adopted and implemented **by and between** all concerned stakeholders in the CELAC and EU countries. According to:

- **✓** EU Drug Strategy 2013-2020 & Action Plan
- ✓ Hemispheric Drug Strategy (CICAD/OAS) & Hemispheric Plan of Action on Drugs (2016 2020)
- **✓ UNGASS 2016**
- ▼ The Sustainable Development Goals adopted by the UN General Assembly for 2030





General objective in DDR: Attained a significant number of countries adopting key processes and tools to enhance planning, quality assurance and evaluation (policy & programmes)


Lines of Action:

- ✓ Quality assurance: validation of quality criteria, to progress towards the establishment of national accreditation systems)
- Capacity building in DDR
- Development of planning and evaluation support instruments
- Reinforce/enhance the role of National Observatories on Drugs





PLANNING MODEL ADOPTED: Serving needs & priorities expressed by countries





COPOLAD II: Progress oriented





Interested countries' commitment to enhance / implement processes & tools within their drug policy (legislation, regulatory frameworks / capacity building strategies / use of supporting tools)





HOW is COPOLAD supporting quality assurance?

Consensus process (starting in 2011) & validation exercise (starting in 2016) including:

- Review of previous developments
- Institutional input
- Expert/professionals input
- Validation instruments and training
- Piloting methodology



Bases of de consensus process of COPOLAD Criteria of Qualiy & Evidence (2011-2014)




Year	Editor	Document
1997	WHO	Life Skills Education for Children and Adolescents in Schools
2008	UNODC/WHO	Principles of Drug Dependence Treatment
2009	WHO	The WHO Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence
2011	EMCDDA	European Drug Prevention Quality Standards
2011	UNODC	The Non-medical Use of Prescription Drugs, Policy Direction Issues
2012	CICAD	Guide to Preventing Prescription Drug Abuse
2012	UNODC	TREATNET. Quality Standards for Drug Dependence Treatment and Care Services

- CICAD (2012). Guide to Preventing Prescription Drug Abuse. Washington DC: Inter-American Drug Abuse Control Commission.
- UNODC (2012). TREATNET. Quality Standards for Drug Dependence Treatment and Care Services. Vienna: United Nations Office on Drugs and Crime.
- WHO (2012). WHO Quality-rights: Assessing and Improving Quality and Human Rights in Mental Health and Social Care Facilities. Geneva: World Health Organization.
- UNODC (2013). International Standards on Drug Use Prevention. Vienna: United Nations Office on Drugs and Crime.
- CICAD (2014). Guía de criterios indispensables para la apertura y el funcionamiento de centros de tratamiento para personas con trastornos por consumo de sustancias psicoactivas. Washington DC: Comisión Interamericana para el Control del Abuso de Drogas.



Previous developments review evidence





Main outcomes 1st phase (2011-1014) LA countries





http://copolad.eu/en/publicacion/45

174 quality standards


NUMBER OF CRITERIA FOR VALIDATION AND PILOT TEST 2017								
	BASIC				ADVANCED			
CRITERIOS	Structural	Functional or process	Evaluati on	TOTAL	Structural	Functional or process		TOTAL
COMMON TO ALL DDR SERVICES/ PROGRAM	12	4	2	18	15	8	2	25
PREVENTION	0	30	12	42	0	37	15	52
RISK REDUCTION	0	3	1	4	0	4	1	5
TREATMENT	12	24	3	39	16	32	5	53
HARM REDUCTION	1	1	0	2	4	1	0	5
SOCIAL INCLUSION	6	9	4	19	9	21	4	34

- A literature review, updating evidence for DDR interventions, published in Spanish
- Identified strategies to support and facilitate progress towards the establishment of national accreditation systems (validation/exchange of best practices/maintained South-South support)
- Commitment of national and multilateral institutions to promote dissemination and support piloting follow-up: Validation by piloting quality criteria in various countries was considered a necessary step





Phase 1 & 2 (2016-2019) with the Caribbean






- Prevention criteria
 (4 countries): Antigua & Barbuda,
 Dominica, Guyana y Jamaica
- Treatment criteria
 (4 countries): Bahamas, Jamaica,
 Saint Lucia, and Trinidad & Tobago





Leading country: Trinidad & Tobago National Drug Council (NDC)





COPOLAD II



Quality Assurance & Capacity building in DDR

22 CELAC countries initiated Piloting-Validation of quality criteria 21 CELAC countries completed Piloting-Validation of quality criteria

LEADING COUNTRIES:

- National Service for the Prevention and Rehabilitation of Drug and Alcohol Consumption (SENDA-Chile)
- Costa Rican Drug Institute (ICD- Costa Rica)
- National Drug Council (NDC- Trinidad & Tobago)

SOUTH- SOUTH COOPERATION





Initial regional training meetings on protocols with each group

Latin America: Criteria in treatment and harm reduction Leadership: Chile

March 2017, Santiago, Chile



Latin America: Criteria in Prevention and risk reduction Leadership: Costa Rica

September 2017, San José, Costa Rica



The Caribbean: Criteria in Treatment and Prevention Leadership: Trinidad & Tobago

April 2018, Kingston, Jamaica






Common methodology. all countries



- A Working Expert Group (WEG) Coordinator based in each country
- Setting-up of a Multisectoral Panel to involve all stakeholders
- Protocols:
 - ✓ Language validation protocol
 - ✓ Indicators and verifiers protocol
 - ✓ Piloting protocol



- Review and validation of the language of the agreed criteria, by the WEG
- Selection of services / programs in each country
- Proposed indicators and verifiers for each quality standard in each country with the local Expert Group
- Piloting (public services or private with public financing)
- Systematization of results by country





Expert Group	N° experts	
LA Treatment Basic	36	
LA Treatment Advanced	55	
LA Prevention Basic	40	
LA Prevention Advanced	27	
The Caribbean P&T	12	



CARIBBEAN

National Multisectoral Panels: Drug Commission, Ministry of Health, Ministry of Education, Universities, Civil Society, Drug Observatories, others...



ARGENTINA



PANAMÁ



CHILE



International review meetings



Latin America:

Treatment and harm reduction criteria

Leadership: Chile

Prevention and risk reduction criteria

Leadership: Costa Rica

November 2018, Santiago, Chile



The Caribbean:

Treatment and Prevention criteria

Leadership: Trinidad y Tobago

June 2019, Paramaribo, Suriname







RESULTS & GOOD NEWS UP TO JUNE 2019







Validation and Piloting completed in 22 countries


(out of 23 participating)


PREVENTION BASIC	PREVENTION ADVANCED	TREATMENT BASIC	TREATMENT ADVANCED	CARIBBEAN		
(L.A.)	(L.A.)	(L.A.)	(L.A.)	PREVENTION	TREATMENT	
Argentina Guatemala Honduras	Chile Colombia Costa Rica	El Salvador Guatemala Honduras	Argentina Chile Colombia	Antigua & Barbuda	Bahamas	
México Panamá		México Panamá	Costa Rica Cuba	Dominica	Jamaica	
Perú Venezuela		Paraguay* Perú	Ecuador Uruguay	Guyana	Saint Lucia	
+RIOD in: Argentina & Dom. Republic		Venezuela		Jamaica	Trinidad & Tobago	





Common DDR criteria at the treatment sector: some results











Treatment criteria: some results









Countries with the piloting completed:

Promising developments of normative/legal frameworks for accreditation in 20 countries

Newly interested countries:

Harmonization of UNODC-WHO International Standards and COPOLAD Standards on:

'Essential Standards' + Quality Assurance tools and mechanism









POLICY RESPONSES

RISK & PROTECTIVE FACTORS

Personal

Familiar

School

Neighbourhood

Community

Environment

Prevention

- Environmental
- Universal
- Selective
- ✓ Indicated

Treatment

- Brief intervention
- ✓ Specialized
- Harm reduction
- Social integration

Settings

Standards

Tools





On-line Courses





Regional Editions

Latin English America Caribbean



381

- ✓ High turnover rates (Decision makers/Officers)
- ✓ Territorial dispersion
- ✓ Limited time to invest in training



Planning & evaluation







Welcome to One Step@a Time Interactive support system for drug demand reduction



Q






intervention planning and evaluation

PLANNING STAGES +










Working tools in the field of drugs

policies



Planning & evaluation

EVALUATION INSTRUMENTS BANK









THANK YOU KINDLY

Teresa Salvador-Llivina

tsl@copolad.eu